LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 3123U 
Lipoxen PLC 
23 June 2009 
 

+--------------------------------------+--------------------------------------+ 
| For immediate release                |                         23 June 2009 | 
+--------------------------------------+--------------------------------------+ 
 
 
Lipoxen plc 
('Lipoxen' or 'the Company') 
 
 
New Evaluation Agreement Signed with Major Pharma Company 
 
 
 Large Pharma Collaborations Now Running on All Three Lipoxen Technology 
Platforms 
 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, announces today that it has signed a new technology evaluation 
agreement ("the Agreement") with an undisclosed leading global pharmaceutical 
company ("the Pharma Company"), for the use of Lipoxen's siRNAblate gene 
silencing technology platform in combination with the Pharma Company's target 
siRNA. 
 
 
Under the Agreement, the Pharma Company will fund and execute a structured 
programme to evaluate and analyse the effectiveness of combining the siRNAblate 
technology with the Pharma Company's siRNA, with the aim of enhancing efficacy 
of the siRNA via improved delivery. This programme mirrors evaluation 
experiments with siRNA that Lipoxen has already successfully conducted and 
replicated in its own laboratories. 
 
 
The evaluation programme is expected to be completed by the Pharma Company in Q3 
2009. If the evaluation is successful, the Agreement may progress to a full 
development and licensing agreement. 
 
 
Commenting on the Agreement, M. Scott Maguire, CEO of Lipoxen, said: "Lipoxen 
now has collaborations with some of the world's largest pharmaceutical companies 
across all three of our technology platforms. We are confident that the 
completion of this evaluation programme by a well known global pharmaceutical 
company will lead to further work on siRNA delivery, and potentially to a 
licensing deal." 
 
 
- Ends - 
For further information please contact: 
 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7389 5015  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   +44 (0) 20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye  |                         | 
| Dietrich, Catherine Breen                       |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
Notes for Editors 
 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines. Lipoxen has three proprietary patented 
technology platforms: 
 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
 
Lipoxen has multiple drug and vaccine programmes in development. Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and Factor VIII through an exclusive 
license with Baxter, the global healthcare company. 
 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities. Lipoxen currently has commercial agreements with some of 
the world's leading biotechnology and pharmaceutical companies including Baxter, 
Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, 
Genentech, Amgen and Genzyme.  Furthermore, Baxter led the GBP2.9 million 
fundraising that the Company announced in May 2009, with a US$1 million 
investment. 
 
 
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London 
Stock Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGRUURBRKWRNUAR 
 

Lipoxen (LSE:LPX)
Historical Stock Chart
From Mar 2025 to Apr 2025

Lipoxen (LSE:LPX)
Historical Stock Chart
From Apr 2024 to Apr 2025